Latest News
A convertible note offering spooked investors.
Via The Motley Fool · September 15, 2026
The Vanguard Energy ETF may be a surprising choice in advance of a Fed rate hike, but it's got history on its side.
Via The Motley Fool · September 15, 2026
This under-the-radar tech stock boasts a Superscore of 72 from our Hidden Gems Primary database, part of The Motley Fool's Moneyball Database system. Here's why.
Via The Motley Fool · September 15, 2026
Stock retains a stake worth ~$15 million following a sale under a pre-established Rule 10b5-1 trading plan adopted in February 2026.
Via The Motley Fool · September 15, 2026
Nvidia stock is not for the faint-hearted.
Via The Motley Fool · September 15, 2026
The rocket launch and satellite specialist just reached an important milestone in its historic acquisition.
Via The Motley Fool · September 15, 2026
Will the Clarity Act pass?
Via The Motley Fool · September 15, 2026
Insider disposition represented 18% of directly held equity, leaving executive with 3,728 shares valued at roughly $900,000 post-transaction.
Via The Motley Fool · September 15, 2026
The drugmaker has a lot riding on continued clinical progress.
Via The Motley Fool · September 15, 2026
Palantir's growth story is changing fast. See why commercial AI could reshape the company's earnings power, and why its premium valuation makes the next phase so important.
Via The Motley Fool · September 15, 2026
Bitcoin fell 4% Tuesday morning.
Via The Motley Fool · September 15, 2026
These chipmakers operate in entirely different parts of the data center supply chain.
Via The Motley Fool · September 15, 2026
Should investors treat Saylor's forecast for 30% annualized returns for Bitcoin over the next 20 years as a buying signal?
Via The Motley Fool · September 15, 2026
Healthcare stocks Eli Lilly, UnitedHealth Group, and Johnson & Johnson offer options for investors of different ages, combining growth potential, turnaround momentum, and reliable dividends.
Via MarketBeat · September 15, 2026
Gilead Sciences (NASDAQ:GILD) executives outlined plans to expand the company’s HIV prevention and treatment franchises while advancing oncology and inflammation programs, with Chairman and Chief Executive Officer Dan O’Day describing the company as being at an “inflection point in value.”
Speaking
Via MarketBeat · September 15, 2026
Bill Ackman closed his Netflix position in 2022. A 50% drawdown and a collapsed multiple brought him back.
Via The Motley Fool · September 15, 2026
SpaceX could become one of the greatest companies of our time. But owning the stock today is not for the faint-hearted.
Via The Motley Fool · September 15, 2026
These stocks have been struggling lately, but they could be underrated buys in the long run.
Via The Motley Fool · September 15, 2026
There are rumors that Elon Musk's Tesla may unveil a flying version of the Roadster at an event planned for Oct. 1.
Via Investor's Business Daily · September 15, 2026
The AI chipmaking leader will stay ahead of the resilient underdog.
Via The Motley Fool · September 15, 2026
The cannabis stock has a bright future, but could it really double in price over the next three months?
Via The Motley Fool · September 15, 2026
Curaleaf took a hostile, $4-per-share cash-and-stock tender offer for Aurora Cannabis directly to shareholders after private merger talks stalled, seeking global scale ahead of federal cannabis reforms.
Via MarketBeat · September 15, 2026
American Express could remain a top-three Berkshire Hathaway holding for decades to come.
Via The Motley Fool · September 15, 2026
Altria, Realty Income, and Main Street Capital are all undervalued income plays.
Via The Motley Fool · September 15, 2026
Apple stock fell amid reports of disappointing preorders for the company's new iPhone 18 Pro handsets, which officially go on sale on Friday.
Via Investor's Business Daily · September 15, 2026
